Membership is open to all those with an interest in the quality and integrity of scientific research and development and those working with, or interested in, Good Laboratory, Clinical or Manufacturing Practice regulations or Pharmacovigilance, be they from industry, government, academia or contract research and wherever in the world they are based.
Welcome to the RQA website
As an Association dedicated to informing and advancing its members, we provide status and visibility for individuals concerned with the quality of research in pharmaceuticals, agrochemicals, chemicals and medical devices. Since its beginnings in 1977, the Association has grown and developed to reflect regulatory changes, the impact of regulatory inspection and the changing structure and needs of industry. RQA's purpose is to drive quality and integrity in scientific research and development.
RQA 2016 Annual Conference
The 2016 RQA Annual Conference will be held at the Hilton Hotel Brighton during the 9-11 November 2016.
Latest News Items
Good Laboratory Practice for Nonclinical Laboratory Studies
The Food and Drug Administration (FDA) is proposing to amend the regulations for good laboratory practice (GLP) for nonclinical laboratory studies to require a complete quality system approach, referred to as a GLP Quality System, when safety and toxicity studies support or are intended to support applications or submissions for products regulated by FDA. We are proposing additional management responsibilities and standard operating procedures (SOPs) consistent with the proposed requirement for a GLP Quality System.
European Commission publishes Pharmacovigilance Report
On August 8, 2016, the European Commission (EC) announced the publication of a three-year report that highlights the collaboration between the European Medicines Agency (EMA), the EC, and European Union Member States in the implementation of pharmacovigilance legislation. The report emphasizes that the collaboration has “enhanced the monitoring of the safety of human medicines throughout their lifecycle, for the benefit of patients.” The report describes the activities of the EU system for monitoring drug safety from July 2012, when new pharmacovigilance legislation came into effect, until July 2015. According to EMA, the report shows that the new system has been successful at quickly detecting safety issues and is effectively engaging patients and healthcare professionals